Abnormal protein accumulation within motor neurons of the brain associates with the cause of ALS/MND. Inhibition of the mTOR signaling pathway slows disease progression in certain preclinical models of ALS/MND and is suggested to provide synergy with the ALS/MND standard-of-care drug, riluzole. An alternative mTOR inhibitor, rapamycin, is currently the subject of an ALS/MND clinical trial in humans investigating control of disease progression. Monepantel has a different structure to rapamycin and an apparently better safety profile.
This from classic.clinicaltrials.gov
So this gives me confidence that Monepantel is a new breed of mTOR inhibitor (that as you pointed out, crosses the BBB) and all the spruiking by MT of late isn’t just hype. He’d be very silly to be this confident publicly for less than ideal results to be released in a week or two.
- Forums
- ASX - By Stock
- The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
Abnormal protein accumulation within motor neurons of the brain...
- There are more pages in this discussion • 1,262 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAA (ASX) to my watchlist
(20min delay)
|
|||||
Last
17.5¢ |
Change
-0.010(5.41%) |
Mkt cap ! $71.26M |
Open | High | Low | Value | Volume |
18.5¢ | 18.5¢ | 17.5¢ | $28.23K | 153.1K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
10 | 272911 | 17.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
18.0¢ | 169021 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
9 | 271197 | 0.175 |
9 | 299523 | 0.170 |
7 | 291780 | 0.165 |
9 | 220562 | 0.160 |
1 | 100000 | 0.155 |
Price($) | Vol. | No. |
---|---|---|
0.180 | 169021 | 4 |
0.185 | 56643 | 7 |
0.190 | 341873 | 8 |
0.195 | 105000 | 3 |
0.200 | 404000 | 3 |
Last trade - 10.48am 21/05/2024 (20 minute delay) ? |
Featured News
PAA (ASX) Chart |